In VivoCommit Biologics is a preclinical company developing a new class of therapeutics based on its Bispecific Complement Engager (BiCE) platform to treat autoimmune diseases and cancer. The company is focu
ScripAbcuro Inc.’s venture capital investors showed confidence in the ongoing Phase II/III MUSCLE clinical trial of ulviprubart (ABC008) in inclusion body myositis (IBM) by putting their support behind a $